Reviewer’s report

Title: Risk of De Novo Post-Transplant Type 2 Diabetes in Patients Undergoing Liver Transplant for Non-Alcoholic Steatohepatitis

Version: 2
Date: 9 August 2015
Reviewer: Kalyan Bhamidimarri

Reviewer’s report:

Major:
1) I think there is an unintentional inclusion of HCV related transplants due to inclusion of primary liver malignancy (27.5%). It is known that a significant proportion of the HCC patients are probably due to HCV and thus the control group might not truly represent non HCV controls. This would skew the calculations and would need to be adjusted.


2) The authors themselves published recently regarding certain donor characteristics: donor age, donor h/o DM, DCD to have a significant impact on PTDM (p< 0.0001) in the recipient. The authors include DCD risk in table 2 but it would be pertinent to include the adjusted hazard ratio (aHR) of donor age and donor h/o DM for PTDM in this paper as well.

Younossi ZM et al; The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment pharmacol ther 2014.

Minor:
Line 51, 53, 54: Need to rephrase that the etiology is cryptogenic cirrhosis (it can be clarified later that a majority of them are most likely related to NASH).
Line 56: clarify the sentence “atleast one onset of de novo diabetes”. Do the authors mean one episode of hyperglycemia?
Line 58: How was diabetes diagnosed? Was ADA criteria used to diagnose DM?
Please use diabetes mellitus or DM or PTDM consistently through our the paper.
Line 107: simplify the sentence.
Line 289: epidemic
Table 2: 2nd group is controls not ALD. Please correct

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being
Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.